GSK Financials: Vaccine Sales Drag Down Quarterly Earnings
Despite beating core profit estimates, the UK drugmaker reported a 19% drop in pre-tax profit as shingles and RSV vaccine revenues fell.
By Nathan Brooks ·

GSK reported a 19% decline in pre-tax profit to 1.9 billion pounds for the third quarter, a result that weighed heavily on investor sentiment despite the company exceeding core earnings expectations. The British pharmaceutical group posted 318 million pounds in restructuring charges during the period, with additional costs anticipated in the coming months. Core operating profit increased by 5%, and core earnings per share rose by 1%, both figures landing above analyst forecasts for the July to September quarter.
The market reaction was immediate and negative. GSK shares fell as much as 7% during trading on Wednesday before recovering to close down 3.8%. This drop made the stock the second-largest decliner on the FTSE 100 index. The primary driver of the sell-off was weaker performance in the vaccine division, which has become a central pillar of the company's recent strategy.
Total revenue reached 8.9 billion pounds, up 5% year over year, driven by strong sales in HIV, cancer, and lupus treatments. However, vaccine sales slipped 2% to 2.6 billion pounds. The flagship shingles vaccine, Shingrix, saw sales drop by 5%, while the respiratory syncytial virus vaccine Arexvy fell 24%. Miels noted that the Arexvy decline was partly due to difficult comparisons with the previous year. Conversely, meningitis vaccine sales grew by 12%, and the newly launched asthma drug Exdensur also underperformed relative to analyst models.
CEO Luke Miels, who assumed the role from Emma Walmsley in January, defended the company's market position. He stated that GSK maintains leadership in market share compared to Pfizer, particularly outside the United States. Miels indicated that the company needs a few more months to see the full picture of vaccine demand. Under his leadership, GSK has pursued several acquisitions, including a 7.9 billion pound deal for a US cancer specialist, and initiated a cost-saving program in July to accelerate drug development.
The company is currently executing a restructuring plan that will cost 2.4 billion pounds, with the majority of expenses occurring in 2026 and 2027. Miels stated that the firm is slightly ahead of its three-year target to save 1.9 billion pounds annually. He noted that the impact on the UK will be limited, with roles in human resources and procurement affected at the London headquarters and hubs in Poland and India. Additionally, GSK is reorganizing its vaccine operations in Belgium, where digital automation is expected to eliminate approximately 1,200 jobs.
Investors remain focused on the upcoming loss of patent protection for dolutegravir, a major HIV drug, which is expected near the end of the decade. This event will allow competitors to introduce cheaper generic versions. To offset this, GSK has set a target of over 40 billion pounds in annual revenue by 2031. The company maintains its annual forecasts and expects to begin 22 late-stage studies of new medicines by the end of the year.
Miels highlighted the potential of Shingrix to grow next year, calling it a remarkable product. Two large studies are currently examining whether the vaccine reduces the risk of dementia and major cardiovascular events. Initial data for these studies is due in 2029 and 2027, respectively. Miels suggested that positive results could be transformative for the product's longevity and market appeal.
More Business · World news · Business Complaints · Report a business · Got a Story?






